KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.

Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L Pangan, Peter Wung, In-Ho Song

Ann Rheum Dis 81(11) 1515-1523

PMID35788492
PMCIDPMC9606523
DOI10.1136/ard-2022-222608
发表日期2022-07-05
入排依据:The study is a phase 3 randomized trial of a drug (upadacitinib) with original results, but it is not an oncology study (it is for ankylosing spondylitis, a rheumatic condition). Furthermore, the primary endpoint (ASAS40 response) is not a time-to-event endpoint like OS/PFS/DFS, and no Kaplan-Meier analysis or hazard ratio is indicated in the abstract.
摘要

摘要

OBJECTIVES: To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs). METHODS: Adults with active AS who met modified New York criteria and had an IR to one or two bDMARDs (tumour necrosis factor or interleukin-17 inhibitors) were randomised 1:1 to oral upadacitinib 15 mg once daily or placebo. The primary endpoint was Assessment of SpondyloArthritis international Society 40 (ASAS40) response at week 14. Sequentially tested secondary endpoints included Ankylosing Spondylitis Disease Activity score, Spondyloarthritis Research Consortium of Canada MRI spine inflammation score, total back pain, nocturnal back pain, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index and Maastricht Ankylosing Spondylitis Enthesitis Score. Results are reported from the 14-week double-blind treatment period. RESULTS: A total of 420 patients with active AS were randomised (upadacitinib 15 mg, n=211; placebo, n=209). Significantly more patients achieved the primary endpoint of ASAS40 at week 14 with upadacitinib vs placebo (45% vs 18%; p<0.0001). Statistically significant improvements were observed with upadacitinib vs placebo for all multiplicity-controlled secondary endpoints (p<0.0001). Adverse events were reported for 41% of upadacitinib-treated and 37% of placebo-treated patients through week 14. No events of malignancy, major adverse cardiovascular events, venous thromboembolism or deaths were reported with upadacitinib. CONCLUSION: Upadacitinib 15 mg was significantly more effective than placebo over 14 weeks of treatment in bDMARD-IR patients with active AS. No new safety risks were identified with upadacitinib. TRIAL REGISTRATION NUMBER: NCT04169373.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。